NASDAQ
03.09.25 | 22:00
1,830 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | BeyondSpring Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08. | BeyondSpring GAAP EPS of -$0.10 | 1 | Seeking Alpha | ||
| 13.08. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | BeyondSpring reports positive results for Plinabulin combination in ICI-resistant tumors | 1 | Investing.com | ||
| 07.07. | BeyondSpring, Inc.: BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure | 2 | GlobeNewswire (USA) | ||
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 03.07. | BeyondSpring plant Jahreshauptversammlung für den 15. September | - | Investing.com Deutsch | ||
| 03.07. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | BeyondSpring reports promising phase 2 NSCLC study results | 4 | Investing.com | ||
| 03.06. | BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.05. | BeyondSpring GAAP EPS of -$0.08 | 2 | Seeking Alpha | ||
| 12.05. | BeyondSpring, Inc.: BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update | 172 | GlobeNewswire (Europe) | Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapySEED's first-in-class RBM39 degrader, reported... ► Artikel lesen | |
| 12.05. | BeyondSpring Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | BeyondSpring GAAP EPS of -$0.21 | 1 | Seeking Alpha | ||
| 27.03. | BeyondSpring Inc. Full Year Loss Declines | 1 | RTTNews | ||
| 27.03. | BeyondSpring, Inc.: BeyondSpring Files 2024 Annual Report on Form 10-K | 1 | GlobeNewswire (USA) | ||
| 27.03. | BeyondSpring Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | BeyondSpring, Inc.: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones | 175 | GlobeNewswire (Europe) | Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential... ► Artikel lesen | |
| 27.03. | BeyondSpring Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.11.24 | BeyondSpring, Inc.: BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior ... | 175 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 16,900 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 40,170 | -0,05 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| BEAM THERAPEUTICS | 18,760 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| NUVALENT | 79,54 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,250 | 0,00 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
| CG ONCOLOGY | 28,670 | 0,00 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,880 | 0,00 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
| AVIDITY BIOSCIENCES | 47,615 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| IMMUNOVANT | 16,700 | 0,00 % | Why Immunovant Stock Blasted Higher Today | ||
| KALARIS THERAPEUTICS | 4,570 | 0,00 % | Kalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates | Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular... ► Artikel lesen | |
| EVOTEC | 5,860 | +1,21 % | Deutsche Bank Aktie: Viel zu teuer? - Evotec, Hensoldt, Nel ASA, Nvidia und Vossloh im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,550 | 0,00 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,630 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| 89BIO | 9,240 | +0,54 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,530 | +0,04 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress |
BEYONDSPRING INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.